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The fourth quarterly report required by the contract under which this
work has been carried out, covers the months of July, August and September
1953, and includes ten formal experiments (CD 20-29) cataloged below.
List of experiments herein reported.
CD 20 - Supernatant III from untreated standard suspensions of leukemia
lb, coTipared with supernatant III after rotation at 37°/30 rain, challenged in
1 hour and 20 days.
21 •• Supernatant III from untreated lb challenged in 6 days; rotated
at 37®/30 riiin., challenged in 6 days and in 25 days.
CD 22 - Repeated CD 20.
CD 23 - Supernatant III from untreated I^: 1) mixed with challenging
dose (U"Q) and injected at once and after roation at 370/6O rain.
2) challenged after 1 hour,and after 22 days.
CD 2h - Repeated CD 23.
CD 25 - Supernatant V (86OO G) challenged in 1/2 hour and after
20 days (li~®).
CD 26 - Repeated CD 25, using challenge dose of U"®.
CD 27 - Supernatant V (86OO G) as compared with supernatant HI (5500 G)
challenged (U"8) "at once".
CD 28 - Repeated CD 27 except each supernatant from a different standard
suspension but the same challenging suspension.
CD 29 - Repeated CD 28 with an added group - supernatant III (11,000 G),
EXPEREiENTS
CD 20.
The rotation (at 37°) of a standard suspension of line leukemia before
centrifuging was indicated, by CD 19, to be unnecessary for the protective
effect of supernatant III, This is confirmed by experiments CD 20, 21 and 22,
In CD 20, section I, a more rigid test was made ly centrifuging one part of a
single standard suspension of line I^ cells without any treatment and the
other part after rotation in 37°/30 irdn. The supernatant III (5500 G) from
each of these sources was injected into a group of mice and both groups were
challenged in an hour with the same dilution (U"®) of leukemic cells. Section
II of this experiment, started independently with another lot of leukemic
spleens used only untreated standard suspension from which supernatant III was
injected into 2 groups and challenged respectively in an hour and in 20 days.
The resistance shown in the 20 day group was comparable to that at any
other times tested (U/lO survived), Ihis was highly surprising because in the
work with line I|j leukemic cells subjected to li6o C for lU min., protection
was given in 2 days, but by a week it had virtually gone, unless a very few
untreated leukemic cells were added to the heated ones, or the length of
heating reduced to 7 min,, in which case a very few leukemic cells remained
intact. Both of these cases give good resistance at 20 days.
Could it be that supernatant III (3 x 5500 G/lO+5 min.) might still in
clude a very few leukemic cells? In this case there were not enough cells
(if any) in the supernatant III to produce leuke)nia in 20 days but in CD l8
the supernatant III, challenged in 6 days (group D), gave 2 deaths 3 days
ahead of the first death of the controls.
In CD 20, Section II, the repetition of the imiaediate challenge after
supernatant III from untreated standard suspension (E), was apparently without
result, since 9/lO of the controls in the challenging dose survived, and the
one death was delayed* In spite of ell efforts to interpret and avoid them,
such failure of the controls has seriously interfered with several of the
experiments in this last quarter, even involving the last experiment, CD 29,
After so many experiments in which the controls regularly died, and the cor
relation between dosage and the time of the appearance of big spleens has been
so high that these have been produced unfailingly on the date desired, it
might be supposed tliat an intrinsic change in the properties of the leukemic
cells might account for this unexpected survival of controls.
But this cannot be the correct interpretation, because along side of the
cases of failure, other controls have given the expected 100^ deaths. Differ-
ences in the number of cells in dilution it"® arising from variations in
accuracy of weighing spleens, or measuring saline, or from differences in the
length of time between killing the spleen donor and inoculating the diluted
dose of cells with the hosts can account for differences of a day or even two
in the average intervals before death, but not for the survival of controls.
A possible interpretation has been suggested, covering all the observations,
by the results of the final experiment (CD 29) when an experimental test of
its validity was no longer possible.
The site of inoculation has always been swabbed with alcohol before the
needle is inserted. If instead of being moistened the hair is dripping wet
with alcohol, this may wet the needle upon withdrawal. If the needle is re
turned quickly in this condition to the vial containing the U"® dilution of
cells, an appreciable amount of alcohol may be introduced - especially when
the volume of the cell suspension is small. One of the precautions devised
against survival of controls has been to mix only small volumes in the final
step of dilution It"®, for there has been considerable evidence that the last
syringefuls from volumes, say, of 10 ml, have lost some potency. Certain it
is that in some cases the hair has been dripping wet with aloohol and in other
cases only moistened. Just when the use of such excess alcohol began is un-
certain^ but it seems probable tliat it was a result of the growing pressure
that developed tliis early suriiraer and eliminated every seemingly unnecessary
movement - such as squeezing out the cotton before applying the alcohol. This
could account for a reduction in the lathality of the challenging suspension
in any syringeful after the first, according to how much alcohol was applied
to the hair of the mouse given the last dose of that syringeful (5 mice per
box, 5 doses per syringeful). The controls have alvjays been inoculated after
the test group. This could account for a gradual weakening of the U-8 dilu
tion in a big series of inoculations; it could also account for the abrupt
loss of lethality that appeared in both sections of CD 29.
Returning to CD 20 - in Section II the first syringeful of the challeng
ing dilution given to group E, resulted in 2 deaths on the 11th day and 3 sur
vivors; the second syringeful given to the first control box El gave 1 death
at the limit of 13 days and U survivors; the third syringeful given to the
second box of tests, E2, as well as the fourth syringeful given to the second
box of controls gave no deaths at all. It is entirely possible tliat the re
sults of the first syringeful are valid - that 3/5 survived on account of the
prior injection of supernatant III. In the following three boxes, the sur
vivors may have received challenging doses rendered sub-lethal by alcohol
introduced when the syringe was returned for the second filling and the usual
ten squirts given to insure uniform distribution of the cells.
CD 21.
In comparing supernatant III from rotated and untreated standard suspen
sion of lb as challenged in 6 days, this experiment was divided into two in
dependent sections for preparation and injection of the supernatants but on
the 6th day, one challenging dilution of li-8 was used for all the micsr,
Besides this^ one box of 5 ruice in each section iiias injected with supernatant
III from rotated standard suspension and not challenged until the 25th day.
In the first section, after supernatant III from rotated suspension (Al)
l/S sxirvived] against 3/5 after supernatant III from untreated suspension (Cl)j
and 5/0 - controls (Dl), In the second section, 2/5 survived in the "rotated"
group (A2), 5/5 survived in the "untreated" group (C2) and 5/5 controls (D2)
survived* Since all these mice were inoculated with dilution U"® from the
same vial, one syringeful per box of five in the above order, it is evident
that the last two syringefuls had lost their lethality. This sudden change
between the fourth and fifth syringefuls was preceded by a progressive
lengthening of the intervals before death of the mice that died. At the time
this seejned to indicate a deterioration with time (although the dilution vial
was kept in crushed ice), so in subsequent experiments, when more than four
syringefuls were required of the same challenging dilution, the last step of
diluting was duplicated in two vials* It should be noted that settling out of
the cells could not account for the failure of the last syringefuls, for the
suspension was thoroughly agitated before each syringeful was withdrawn, by
60 syringe squirts of 1 ml in blending the dilution at first, and 10 squirts
before each successive sjTingeful,
Although incomplete, this experiment gives evidence that supernatant III
from both rotated and untreated standard suspension gives resistance at 6 days,
comparable to that appearing earlier* Further, groups B1 and B2, injected
with supernatant III from the rotated standard suspension showed comparable
resistance when challenged in 25 daysj 3/lO survived, against O/lO controls on
challenging dose (U**®),
CD 22*
The effect of rotating standard suspension at 37° was further checked by
comparing supernatant III from rotated and untreated cell-suspension challenged
in an hour# One group (C1 and C2) with "untreated" supernatant III was not
challenged at once but held as controls on the possible lethality of the
supernatant. The two sections of this experiinent were performed entirely
independently with different challenging dilutions, on successive days# Again
the rotation seemed to have no effect - all the controls died and the unchal
lenged group in the first section (Cl) developed no signs of leukemia until,
after 22 days, it was challenged and l/5 survived# 3ut the unchallenged
g3?oup in the second section (C2) developed two cases of leukemia with death on
the 13th day# This is the first direct evidence of leukemic cells in super
natant III, although the delayed challenging in this and earlier experiments
was planned primarily to check this possibility which had been suggested by
the death of two mice with supernatant III two days ahead of the
earliest death known for that challenging dose.
CD 23
Since some resistance can be established when the challenging dose (#2 ml
dilution ii-8) is given an hour after superiiatant III (1.0 ml) from untreated
standard suspensions, the question is raised whether the material responsible
for this resistance acts upon the leukemic cells directly or upon the host#
To approach this question, the challenging dilution was mixed with supernatant
III before injection in the proportion of 0.2 : 1.0 with 1.2 ml per dose# One
group of mice was inoculated at once, another group inoculated after the mix
ture of supernatant III and challenging dilution had been incubated for 1 hour
by rotation in 37°. Controls (Dl) were inoculated after the unmixed portion
of the challenging suspension had been held in the cold room (2°) for one hour,
m of the above was performed twice, independently from the beginning, with
the addition, in the second section, of a group (2 boxes C1 and C2) injected
with supernatant III alone, and challenged with the controls (D2) in one hour#
This entire experiment, including (fpr the first time) the preparation of the
challenging dilution, was performed in the cold room (2®), anticipating excel
lent results• But of the UO mice included in the two sections only 3 died,
and these were in the first section with the mixture given before rotation
(A1)• Alcohol carried over on the needle could explain the survival of con
trols in the first section but not the unexpected survivors in the first box
of the second section. At the time it seemed suggestive that the challenging
dilution in this and in no other experiment was prepared in the cold room. In
the following repeat experiment, in which all other procedures were carried
out in the same way except that the challenging dilution was made in the
laboratory instead of in the cold room, the results are significant#
CD 2lt.
The repetition of CD 23 included the same groups with the exception of
the group given supernatant III alonej replacing this, a group (C1 and 2) was
given the challenging dose after it (alone) had been rotated 37®/60 min. Olie
two independent sections of this experiment gave identical results and can be
combined. AH controls died, and h/lO survived the mixture of supernatant III
and challenging dilution - (1.2 ml dose) inoculated at once. However, all
those given the incubated mixture survived lO/lO. This would have seemed an
eimpliatic answer to the question of direct action of supernatant III upon the
cells, hiad the rotation of the clallenging dose alone been omitted. But all
of this group (Cl and 2) also survived - so that the survival of the group
with the rotated mixture depended upon the effect of the rotation in 37® upon
the leukemic cells, rather than the effect of supernatant III upon them.
CD 25.
If leukemic cells in supernatant III are responsible for the resistance
found at 20 days, supernatant after more intense centrifugation should fail
8to give any protection at this time. Will the complete removal of leukemic
cells wipe out the resistance to immediate challenge? The rest of the experi
ments were directed toward these questions. Supernatant III (3 x 5500 G) is
slightly clouded, and in the last run some sediment is thrown down. By in
creasing the speed of the centrifuge to give 8600 G, and increasing the number
of runs to five, a brilliantly clear supernatant V was obtained, which gave no
visible sediment after the fifth run. Beginning with this experiment the use
of the cold room was given up entirely. In CD 25, two groups were given
supernatant Vj one group challenged at once, one group in 20 days. In view of
the recent survival of controls and at that time suspecting an intrinsic
change in the potency of the leukemic cells, the immediate challenge was in
creased to In each section of the experiment all the supernatant V mice
died.
Before the time for the 20 day challenge, dilution in other experi
ments was killing all the controls, so that any intrinsic reduction in the
virulence of the leukemic cells seemed ruled out. Accordingly dilution it"®
was used for the 20 day challenge utilizing the ii~® dilution prepared for the
second section of CD 27. When this second section of CD 27 was being carried
out, only one possible donor for the immediate challenge remained alive, and
this one died naturally a few minutes before its spleen would have been taken.
Since the mouse was hardly cold when the spleen was removed, no trouble was
anticipated, but all the fifteen controls inoculated with the ii"® dilution
from this spleen survived, as well as 17 of the 20 mice in the test groups.
As had become the practice, the U"® dilution was made in two vials, a different
syringe for each vial. It is interesting that the first syringeful from each
vial was responsible for the three deaths that did follow. In this case, and
in all other experiments, the deaths have invariably resulted from leulvemia,
with typical spleens.
CD 26.
Again supernatant V was used for challenge at once and in 20 days.
Although the challenge dose was all treated and control mice died promptly
after the immediate challenge. From the 20 cay challenge l/lO survived, but
the litter-mate of this one in the controls also survived.
The question raised under CD 2i> is unanswered and the termination of the
contract prevented further cliallenging at 20 days. There remained opportunity
to compare supernatant V and supernatant III when challenged at once.
CD 27.
In order to start with the same material to produce supernatant III and
supematant V and control the time and the temperature of larger and faster
centrifuging, all the required standard suspension was placed in one centrifuge
tube and the supernatant III (3 x 5500 G/lO+5 min.) prepared. Then this was
divided between two tubes, one of which was given 3 x 8600 G, and the superna
tant removed each time to a clean tube to produce what will be called superna
tant "V"j the other tube was given the same centrifuging but each time the
sediment was resuspended xdthout removal of the supernatant, leaving it super
natant IIIc In the first section of the experiment, l/5 given supernatant III
survived and 0/5 survived given supernatant "V" - all controls died. In the
second section, the donor of the challenging dilution had died naturally as
already mentioned and the only death was from the first syringeful, one mouse
given supernatant "V" - which died on the lltth day. On the chance that the
challenge had not included enough cells even to immunize, these three groups
were reinoculated 12 days later in connection with the final experiment, CD 29.
All of the reinoculated controls died, as well as all of the previously unin-
oculated controls; of the group given supernatant III 3/5 survived and of the
group given supernatant "V" 3/li survived. The prompt death of the controls
makes this result seem to have some significance for the comparison of superna-
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tants III and "V". Compared with the first section of this experiment these
proportions of survivors are high and a suspicion is raised that in the
original challenge there may have been enough cells in the first two syringe-
fuls to partially immunize {witness one death), but the last syringeful given
to the controls had been reduced below the immunizing level, perhaps by
alcohol carry-over.
CD 28.
Instead of starting with the same standard suspension of I|j for both
supernatants III and V, in this experiment the two supernatants (III « 3 x
5500 Gj V B 5 X 8600 0) were centrifuged independently from different standard
suspensions but within each of the two sections, were challenged by the same
^ ^  dilution. Thus, group A was challenged an hour after treatment with
supernatant V, and group B challenged a few minutes after treatment with
supernatant III, In the first section, after supernatant V, 1/5 siirvivedj
after supernatant III, 2/5 survived and all controls died; in the second
section, l/5 survived after each supernatant and l/5 of the controls. On face
value, the second section is completely negative. In comparison with the
first section and considering the uncontrolled phenomenon of deterioration of
dilution It ® in successive syringefuls that has been ©o obviously present in
some cases, it seems altogether probable that the survivors in the first two
groups and in the third (controls) survived for different reasons, and for th?
purposes of the comparison of the two supernatants, the two sections may
reasonably be combined, indicating 2/lO survivors for supernatant V and 3/10
for supernatant III,
CD 23 n
In the first experiment, mice for a fourth staggered group were available,
so CD 28 was repeated with the addition of a group given supernatant III run
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at 11,000 G, in this way producing a crystal clear supernatant without increas
ing the total time in the centrifuge as required for supernatant V, Within
each section all three groups were challenged with the same 1;"® dilution at the
same time; in group A (supernatant V) this was within 2 hours; in group B
(supernatant III, G) this was in 1 hour; and for group C (supernatant III,
11,000 G) this was in a few minutes.
The results were disconcerting but dramatic. All the controls on dUution
U"® in each of the two sections survived although half of the supernatant-
treated mice died. In the first section the deaths occurred in the first two
syringefuls of dilution U-8; the 3rd syringeful (Cl, supernatant III, 11,000 G)
as well as the l|th syringeful (controls) gave 5/5 survivors. The total time
elapsed in inoculating was less than 20 minutes. In the second section, the
first three syringefuls gave deaths (3, i;, and respectively) and the fourth
none. It was the abrupt breaks between the 2nd and 3rd syringefuls in the
first section and between the 3rd and l;th syringefuls in the second section
that at long last, in defying every other interpretation that had been devised
for the failure of controls, pointed to alcohol carried over by the needle as
the explanation of the weakening of the virulence of the challenging dose in
successive syringefuls. For this could account for gradual change quite as
easily as for the abrupt changes here exhibited.
In section I, lt/5 survivors after supernatant V (Al) is unusually high;
one of these, however, was a borderline case, with a large spleen, which
nevertheless recovered. With all the supernatant III (11,000 G) mice (01)
surviving, the first impression was that the U**® dilution must have been weak
to start with, but this is not supported by the groups from CD 2? reinoculated
with a second vial of dilution U""® made at the same time from the same
dilution. As described above, the 3rd and bth syringefuls in these reinocula-
tions were fully potent and killed all the reinoculated controls as well as all
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the controls (Uth syringefnl) being Inoculated for the first time. Ely the
time these mice were inoc\alated the watch glass of alcohol for swabbing was
probably running dryi
As it stands the tally of results for this experiment seems to say that
treatment with these supernatants increases the susceptibility of the mice
rather than induce resistance. In view of all that has gone before, this is
untenable. On the other hand, if the evidence of erratic reduction in the
virulence of successive syringefuls of the same dilution is accepted,
whether or not alcohol carry-over is the correct interpretation, one seems
justified to consider the results for A1 and 2, B1 and 2, and C2 as reasonably
good for the comparison of resistance induced by the three supernatants. How
ever fragmentary the evidence in all of these experiments none of it suggests
that the resistance induced by supernatant III (5500 G) is eliminated by more
intense centrifugation.
_L
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CD 20. CSH 2232 lb 2106
CSH 2233 lb 2106
C5H 22US lb 2109
VI.30.1953
Supernatant III from untreated, compared with rotated (37®), standard suspen
sion of lb, challenged at once and in 20 days. This checks CD 19. using a
single original cell suspension.
Groups
Section I A. Supernatant III from untreated standard suspension lb.
B. Supernatant III from rotated (37®/30 nin.) standard suspension
C, Controls on challenge (U"^) given in 1 hour.
Section II D. Supernatant III from untreated standard lb - unchallenged for
20 days, then given
Controls for D challenge.
E. Supernatant III from untreated standard lb.
F. Controls on challenge (U-8) for E, given in 1 hour.
Section I.
7sOO - 9:00 A.M. Prepared standard suspension (ii3.0 ml) in two lots of 9
spleens each; while collecting each lot of spleens held in stainingjar packed in ice and salt. First lot, after suspension, held in
flask packed in ice and salt. Second lot, after suspension, com
bined with first lot and equal volumes, in alternate 2 ml portions,
to centrifuge tube (al) and another flask.
9:00 - 9:35 Flask rotated (SO p^m.) - to tube bl.
9''kS - 10:00 Tube bl - 5500 G/lO+5 min. - supernatant I (1.1; ml) to tube b2.
10:07 - 10:22 Tube b2 - 5500 G/lO+5 nin. - supernatant II (13 ml) to tube b3.
10:30 - 10:i;5 Tube b3 - 5500 G/lO+5 nin. - supernatant III (10,5 ml) to vial,
10,50 - 10:5U Injected 10 group A — 1,0 ml per mouse.
9-05 - 9:20 A.M. Tube al - 5500 G/lO+5 min, - supernatant I to tube r2o
9:25 - 9:1:0 Ibbe a2 - 5500 G/lO+5 min. - supernatant II to tube a3-
9*.1:5 - 10:00 Tube a3 - 5500 G/lO+5 min, - supernatant III to vial nn hald jn
2® room till supernatant from tube b3 ready to inject.
lOfhO - 10sUU Inject 10 cfcT group B - 1.0 ml per mouse.
Hi
11:147 - 12:03 Challenged groups A and B (C = controls) ,2 ml L-8
CSH 2232 lb 2106.
Section n.
1:30 - 3:30 P.M. Prepared ijO.O ml standard Ik in two lots as in Section I.
all in tube dl.
3:32 - 3:ii7
3:55 - 14:10
14:17 - 14:32
hih$ - 14:56
5:59 - 6:C8
VII.20.1953
1:00 Ch
Tube dl - 5500 G/IO+5 min. - supernatant I to tube d2.
Ibbe d2 - 5500 0/10+5 min. - supernatant II to tube d3.
Tube d3 - 5500 G/IO+5 min. - supernatant III to vial.
Injected 1.0 ml per mouse, groups D and E,
Challenged groups E and F (C « controls) CSH 2232 lb 2106,
CSH 22145 lb 2109
allenged (U-S) group D (at that time all negative) and 10 (f
(correlated) controls.
r?
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CD 20 Results
Tirae of death in l/k days after challenge (U~8)
9th 10th 11th 12th 13th Survived
Supernatant III from
standard suspension I^:
1  . . .
Section I, j
A, Untreated 1 1  h 1
B. Rotated - 37V30 11 2 2 1 1 i
C. Controls on challenge
in 1 hour
CSH 2232 lb 2106
'
113 h
Section IE.
D. Untreated -
challenged in 20 d.
1 1 3 1
Controls on challenge
(ii-8 of D
CSH 22h$ lb 2109
2 3 3  11
E. Untreated -
challenged in 1 hour
^2
F. Controls on challenge
(U-8) of E
CSH 2233 lb 2106 j
•JHOL
3/10
2/10
•0/9
li/10
O/lO
8/10
9/10 I
* Inoculated with 1st syringeful.
^ Inoculated with 2nd syringefult
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CD 21. CSH 22iiO lb 2108
Supernatant III from rotated and untreated standard suspension of lb,
challenged in 6 days and in 25 days.
Groups
Section I Al. Supernatant III rotated 37°/30 - challenged in 6 days,
31. Supernatant III rotated 37°/30 - challenged in 25 days.
Cl. Supernatant III untreated - challenged in 6 days.
Dl. Controls on challenge It"® in 6 days.
Section II A2.
B2. I
S  as above
02. I
t
D2. /
Section I.
VII.8,1953
2:05 - i^:lit P.M. Prepared 32.6 ml standard suspension in two lots of 7
spleens eachj combined and divided 2 : 1 between flask and centri
fuge tube C, in alternating k and 2 ml portions. Tube held in cold
room till flask rotated.
I:l5 - U:50 Flask rotated 37°/30+5 min. - to tube al.
hi$5 - 5slO Tubes al and cl - 5500 G/lO+5 min. - supernatants I to tubes
a2 and c2 respectivelj'".
5:20 - 5s35 Tubes a2 and c2 - 5500G/10+5 min. - supernatants II to tubes
a3 and c3 respectively.
5:li5 - 6:00 Tubes a3 and c3 - 5500 G/lO+5 min. - supernatants III 10+ ml
and 5 ml respectively to vials a and b.
6:12 - 6:22 Inject 1 ml vial c to 5 group C.
Inject 1 ml vial a to 10 d'd' groups A and B.
Section II.
6:30 - 8;li5 P.M. Prepared 35.75 ml standard suspension Iv in 2 lots of 9
spleens each; combined and divided in alternate h ml and 2 ml por
tions between flask and centrifuge tube clj which was held in cold
room while flasks rotated.
8:it5 - 9:20 Flask rotated 370/30+5 min. - to flask al.
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9s25 - 9siiO Tubes al and cl » 5500 G/lO+5 min# - supernatants I respectively
to tubes a2 and c2.
9!^? - 10:02 Tubes a2 aiid c2 - 5500 G/lO+5 min. - supernatants II
respectively to tubes a3 and c3.
10:15 - 10:30 Tubes a3 and c3 - 5500 G/lO+5 min. - supernatants III, 10 ml
from tube a3 to vial a.
10:li5 - 10:55 Injected from vial c 1.0 ml per mouse to group C2.
Injected from vial a 1.0 ml per mouse to groups A2 and B2.
VII.11.1953 - CbH 22U0 lb 2108
8:U0 - 9!05 PJT. Cl-jallenged groups Al, A2, 01, 02, and controls D, D2.
VIII,2.1953 - C5H 2255 lb 2111
5iU5 Ohallenged (U-8) groups Bl and B2, and 10 d controls.
'iWii n
Cp23^.esults
18
VII.8.1953
Supernatant HI from
std. suspension I^
In 6 d, challenged
l;-8
GSH 22hO lb 2108
Section I.
8:I;0 P.M.
. Al, Rotated 37V30
8:U5 P.M.
Cl. Untreated
8:50 P.M.
Dl, Controls on
Section II.
8:55 P.M.
A2. Rotated 37O/30
9:00 P.M.
C2. Untreated
9:05 P.M.
D2. Controls on I4."®
In 25 d. challenged
CSH 2255 lb 2111
Section I.
SihS P-M.
E. Controls on U"®
5:U9 P.M.
Bl, Rotated 37°/30
Section II.
5:52 P.M.
B2. Rotated 37°/30
5:56 P.M.
E. Controls on U~8
Time of death in l/h days after challenge (1^-®)
9th 10th 11th 12th 13th llith Survived
1 2 1
1  1
2  1
1
1  1 1 2
1 1
3/5
0/5
2/5
5/5
5/5
0/5
2/5
1/5
0/5
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CD 22, CSH 22lil 2108
CSH 22U2 Iij 2108
CSH 2257 lb 2111
VII.15-16,1953
Further comparison of supernatants from untreated and rotated 37°/30 suspen
sions of lb.
Groups
Section I Al. Supernatant III from rotated 37°/30 standard lb challenged in
1 hour,
Bl. Supernatant III from untreated standard lb challenged In 1 hour.
Cl. Supernatant ni from untreated standard lb challenged in 22
days.
Dl, Controls on challenge of Al and Bl.
Section II A2.
B2. ^
C2. f
as above
D2
Section I.
J
9:10 - 11:25 A.M. Prepared 33.5 ml standard suspension lb (in cold room) in
2 lots of 7 spleens each: combined and divided, in alternate 2 ml
and U ml portions between flask and centrifuge tube bl: tube held in
cold room until flask rotated.
11:30 - 12:05 Flask rotated 37®/30+5 min. - to tube al.
12:13 - 12:28 Tubes al and. bl - 5500 G/lO+5 min. - supernatants I to tubes
a2 and b2 respectively.
12:U2 - 12:57 lUbes a2 and b2 - 5500 G/lO+5 min. - supernatants II to tubes
a3 and b3 respectively.
1:07 - 1:22 Tubes a3 and b3 - 5500 G/lO+5 min. - supernatants III - 5"*" ml
to vial aj 10+ ml to vial b.
1:30 P.M. Inject 1 ml per mouse vial a to group Al.
1:35 Inject 1 ml per mouse vial b to groups Bl and 01.
2:35 - 2;U0 Challenge groups Al and Bl - Dl controls.
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Section II.
VII.16.1953
10:05 A.m. - 12:15 P.M. Prepared 33»9 ml standard suspension lb in 2 lots of
8 and 6 spleensj combined and divided in alternating 2 ml and h ml
portions between flask and tube bl; tube held in cold room until
flask rotated.
12:20 - 12:55 Flask rotated 37° - to tube al.
1:00 - 1:15 Tubes al and bl - 5500 G/lO+5 min. - supernatants I to tubes a2
and b2 respectively.
1:22 - lO? lubes a2 and b2 - 5500 G/lO+5 min. ~ supernatants II to tubes
a3 and b3 respectively.
I:ii3 - 1:58 Tubes a 3 and b3 - 5500 G/lO+5 min. - supernatants III - 5"'" ml
to vial a, 10+ ml to vial b.
2:10 Inject vial a » group A2 - 1 ml per mouse.
2:00 Inject vial b - groups B2 and C2 - 1 ml per mouse.
3:20 Challenge (i:-8) - groups A2, B2 and D2 controls.
VIIIt6.1953 - 2257 lb 2111
5:05 P.H. Challenged C1 (22 d.)
21
CD 22 Results
Supernatant III from
standard lb
Al, Rotated 37° chal
lenged in 1 hour
B, Untreated - chal
lenged in 1 hour
D. Controls on in
1 hour
CSH 22lil lb 2108
CSH 221^2 lb 2108
Cl, Untreated - chal
lenged in 22 days
Controls for Cl
li"® in 22 days
CSH 225? lb 2111
C2. Untreated -
unchallenged
Tirie of death in l/h days after challenge {U"^)
9th 10th 11th 12 th 13 th liith Survived
T  • • •
1
1 3  2 1 1 2/10
1 2  12 1 3/10
2 1  1 2  3 1 0/10
h
1
1
1  1/5
1 3 1
1
i  0/5
i
i
1  1
1
1
I  3/5 i
j
22
CD 23. CSH 22U3
CSH 22hh
VII,17.1953
Is there direct interaction between sunernatant III and the challenging line
lb cells?
Will incubation of the mixture of supernatant leukemic cells increase the
number of survivors?
Groups
Section I Al, 1,2 ml mixture supernatant III and dil, U"® at once.
Bl. 1,2 ml mixture supernatant III after rotation 37°/6G min.
Dl, Controls on dil, after 1 hr. in 2® room.
Section II A2, 1,2 ml mixture supernatant III and dil, ^t once,
B2, 1,2 ml mixture supernatant III after rotation 370/6O rain,
C1 and C2, 1 ml supernatant III (above)
Section I,
CSH 22it3 lb 2108
8:55 - 10:U5 A,M, Prepared 37.75 ml standard suspension lb, in two lots of
8 spleens each, in 2° room, combined in tube 1; mice injected just
outside cold room.
10:50 - 11:10 Tube 1 - 5500 G/l5+5 min.; supernatant I (19 ml) to tube 2.
11:15 - 11:30 Tube 2 - 5500 G/iO+5 min.; supernatant II (17 ml) to tube 3,
Prepare dilution « 2.2 ml to flask in cold room and held there
1 hour.
11:U5 - 12:00 Tube 3 - 5500 G/lO+5 min.; supernatant III (11 ml) to flask,
12:10 Inoculate Al - 1,2 ml mixture from flask per mouse.
12:10 - 1:10 Flask rotated 37°/60 min.
1:10 Inoculate Bl - 1,2 ml mixture from flask after rotation,
12:20 Inoculate Dl - ,2 ml dilution - control.
23
Section II.
1:3$ - 3s50 P»M, Prepared 39»80 nil standard suspension line in two lots
of 10 and 8 spleens - coTnbined in tube 1.
3j$5 - Uj1$ Tube 1 - 5500 G/15+5 min.j supernatant I (2$ ml) to tube 2.
U:20 - U:35 Tube 2 - 5500 G/lO+5 min.; supernatant II (23 ml) to tube 3.
Prepared dil. U-" - 2.2 ml to flask 1 - rest held in 2° room 1 hour.
UjIiP - U:57 Tube 3 - 5500 G/lO+5 min,; supernatant III - 11 ml to flask 1,
10+ ml to vial,
5slU Mix contents of flask and inoculate A2 - 1.2 ml per mouse.
5:ll+ - 6:lli Flask to rotate - 37V60 min.
5:l8 Inject C1 and C2 - 1 ml supernatant III from vial.
Inoculate B2 (1.2 ml per mouse) from flask after rotation.6:15
6:37
O
Inoculate D2 - .2 ml I4, after 1 hour in 2® room and resuspended
by 60 shots.
Results
A1 - A2 - mixture at once
B1 - B2 - mixture rotated
C1 - C2 - supernatant alone
D1 - D2 - controls
Survived
7/10 (3 deaths 13-15 d. = delayj 2
"survivors" had "pads" at 25 d.)
10/10
10/10
10/10 (I)
2U
CD 2lt. Repetition of CD 23
Is there direct interaction between supernatant III and line I^ cells?
Section I. CSH 2251 lb 2111
Al« Supernatant III and dil. it"*® mixed - inoculated at once*
Bl, Supernatant III and dil. it*"® mixed - after rotated 37®/60 min.
01, Dil, it"® after rotation 37°/60 min,
Dl, Controls on dil, it"*® before rotating,
7:30 • 8:55 A.M, Prepared 30.3 ml standard suspension lb in 2 lots of 6
spleens each - combined in tube 1.
9:00 - 9:20 Tube 1 - 5S00 0/15+5 min,j supernatant I (20 ml) to tube 2,
9:25 - 9:i:5 Tube 2 - 5500 0/15+5 min,j supernatant II (15 ml) to tube 3.
9^52 - 10:25 ^be 3 - 7000 0/28+5 min.; supernatant III - 11 ml to flask
II (red).
Prepared dil it"*® -outside cold room in ice - 6,it ml in flask I
(blue).
Removed 2,2 ml it"® to flask II (red) and mixed,
10:23 Inoculate Dl - ,2 ml it"® from flask I,
10:35 Inoculate A1 - 1,2 ml mixture from flask II,
10:37 - 11:37 Flasks I and II rotated 37^/60 min,
ll:itO Flask I - inoculate ,2 ml - Cl,
ll:it5 Flask 11 - inoculate 1.2 ml - Bl,
Section II, CSH 2252 lb 2111
A2, Supernatant III and dil, it*"® mixed - inoculated at once.
32, Supernatant III and dil, U"® mixed - after rotated 37®/60 min*
C2, Dil, it"® (above) after rotated 37®/'50 min,
D2, Dil, it"® at once - controlso
10:it5 - 12:25 P.M. Prepared 31.0 ml standard suspension lb in two lots of
6 spleens each - combined in tube 1,
12:30 - 12:50 Tube 1 - 5500 G/i5+5 min,; supernatant I (j.9 ml) to tube 2,
12:55 " 1:15 Tube 2 - 7000 G/i5+5 min,; supernatant II to tube 3*
25
ltl8 - 1:U9 Tube 3 - 7000 G/26+5 rain.j supernatant III - 11.0 ml to flask
(red) containing 2.2 ml dil. U'°*
Prepared dil, U-o - 6.U ml in flask (blue) - 2.2 ml 1^-8 to flask
(red).
ijiiS Inoculated D2 - .2 ml from flask (blue), then flask to rotator,
2*00 Mix flask (red) inoculated A2 - 1.2 ml per mouse - then
2:02 - 3:02 Flasks (red and blue) rotated 37°/60 min.
3:07 Inoculate C2 - .2 ml from flask (blue) U"®.
3:11 Inoculate B2 - 1.2 ml from flask (red) mixture).
CD2ljJ^ults
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Time of death in l/h days after challenge (U~S)
10th 11th 12th Survived
Section I. 1
CSH 2251 lb 2111
1
Al, Mixture supernatant III and - 1 1 1
inoc. at once
31, Mixture - after rotation
37°/60 min.
Cl, Dilution after
rotation 37°/60 min.
Dl, Dilution at once 2  1 1
Section II.
CSH 2252 lb 2111
A2, Mixture - at once. 1 1 1
32. Mixture after rotation
1
i
02. Dilution after rotation !
D2, Dilution at once 1 3 1
2/S
5/5
5/5
0A *
2/5
5/5
5/5
0/5
* 5th (f killed by accident
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CD_2|. CSH 2256 1^ 2111
CSH 2257 lb 2111
CSH 2261i 2115
VIII,6.1953
VIII.26.1953
V/ill crystal clear supernatant give any protection at once? at 20 days?
Survival of controls on dilution prompted the use of dilution U-6 for the
immediate challenge - ij-S was used at 20 days.
This experiment was performed entirely in laboratory, including centrifuging
for the first time not in 20 room.
Groups
Sections I and II A1 and A2. 1 ml supernatant V - challenged (U"^) at once.
B1 and B2. Controls on
Cl and C2. 1 ml supernatant V - challenged (U"®) 20 days,
D1 and D2, Controls on U"®
Section I.
8!55 - 10:00 A.M. Prepared 29 ml standard suspension lb in 2 lots of 6
spleens each - combined in tube 1.
10:03 - 10:l8 Tube 1 •» 8600 G/lO+5 min.j supernatant I (17 ml) to tube 2.
10:23 - 10:38 Tube 2 - 8600 G/lO+5 min.j supernatant II (16,5 ml) to tube
10:li2 - 10:57 Tube 3 - 8600 G/lO+5 min.; supernatant III (15 ml) to tube
11:02 - 11:17 Tube !i - 8600 G/lO+5 min.j supernatant IV (13 ml) to tube 5.
11:20 • 11:35 Tube 5 - 6600 G/lO+5 min,; supernatant V no sediment visible
11:10 - ll:h5 Supernatant V - 1 ml per mouse to A1 and Cl.
12:07 - 12:10 P,M, Challenged A1 and Bl - ,2 ml CSH 2256 1^ 2111.
Section II,
l:l40 - 2:U0 P.M, Prepared 28,75 ml standard suspension in 2 lots of 6
spleens each - combined in tube
2:1:5 - 3:00 Tube 1 - 8600 G/?0*'-5 min-; ^supernatant I (20 ml) to tube 2.
3:05 - 3:20 Tube 2 - 8600 G/10*5 min.; supeinauent II (l8 ml) to tube 3.
3:25 " 3fU0 Tube 3 - 8600 G/lO;-5 nin,: ►^vp.^rnatant I"^! (l6 ml.) to tube
3:1+5 •• U:00 Tube U - 8600 G/lO+5 min,; supei'natant IV (lit. r.il) to tube 5f>
26
U»05 - U:20 Tube 5 - 86OO G/lO+5 min.j supernatant V no visible sediment,
14:25 - U:30 Inject A2 and C2 - 1 ml supernatant V,
14*55 - 5:00 Inoculate A2 and B2 - ,2 ml CSH 2257 lb 2115.
VIII.26.1953 (20 d. test)
5:28 - 5:38 PJI. Challenged C1 and 02, Dl and D2 - ,2 ml li"®.
CSH 22614 lb 2115.
(Donor of the best spleen available for this challenge died
naturally a few rdnutes before spleen removed.)
CD 25 Results
29
Time of death in lA days after challenge or U"®)
8th 9th 10th
Section I«
Al, Supernatant V -
in 1/2 hr.
CSH 2256 lb 2111
Bl, Controls on
Section II«
A2. Supernatant V -
in 1/2 hr.
CSH 2257 lb 2111
B2. Controls on
Sections I and II.
Cl and C2. Superna
tant V - It-o in 20
days
CSH 226ii lb 2115
(Donor had just
died naturally.)
D1 and D2.
Controls on h"^
1  li
11th 12th 13th Survived
2 *
0/5
0/5
0/5
1/5 I
8/10
lO.'lO I
inoc. 1st syringeful - 2nd vjai
of
30
CD 26. CSH 2259 lb 2112
CSH 2260 lb 2112
CSH 2265 lb 2116
VIII.12.1953
IX.1.1953
Supernatant V - challenged at once (U-8) and in 20 days. Repetition of CD 25.
Groups
Sections I and II A1 and A2, 1 ml supernatant V (8600 G) - from standard
lb - challenged in l/2 hr,
B1 and B2. Controls on challenge (U~®) of A.
Cl and C2. 1 ml supernatant V (as above) - challenged in
20 days.
D1 and D2. Controls on challenge of D.
Section I,
VIII.12.1953
QikO - 9sii5 A.M. Prepared 28 r,il standard suspension lb in two lots of 6 and
5 spleens - combined in tube 1.
9:50 - 10:05 Tube 1 - 8600 G/lO+5 min.j supernatant I (16 ml) to tube 2,
10:10 - 10:25 Tube 2 - 8600 G/lO+5 rain.; supernatant H (l6 ml) to tube 3.
10:30 - 10:U5 Tube 3 - 36CO G/iO+5 min,; supernatant III (l5 ml) to tube !io
10:li8 - 11:03 Tube It - 6600 G/lO+5 min.j supernatant IV (13 ml) to tubs 5»
11:08 - 11:23 Tube 5 - 6600 G/lO+5 min.j supernatant V (no visible sediment),
I1s27 - 11:30 Inject A1 and Cl - 1 ml supernatant V.
11:57 - 12:00 Challenged A1 and B1 - .2 ml It"®. CSH 2259 lb 2112.
Section II.
I2flt5 - 1:1+5 P.H« Prepared 23rltO ml standard suspension lb in 2 lots of 5
spleens each - combined in tube 1.
1:50 - 2:05 Tube 1 - 8600 G/lO-'-5 mint j supernatant I (17 ml) to tube 2.
2:10 - 2:25 Tube 2 - 8600 G/lO+5 min.; eupernatant II (15 ml) to tube 3.
2:30 - 2;it5 Tube 3 - 8600 G/lO+5 min j supernatant III (13 ml) to tube it.
2; 50 - 3:05 Tube It - B600 G/lO+5 mia-i supernatant IV (12 ml) to tube .5^
31
3j10 - 3!25 Tube 5 - 860O G/lO+5 min.; supernatant V 10+ ml to vial -
(very slight sediment).
3:29 - 3:32 Inject A2 and C2 - 1 ml supernatant V. C5H 2260 lb 2112.
Section I and II. (20 d. test)
IX.1.1953
7:57 - 8:06 A.M. Challenged Cl, Dl, 02, D2 - .2 ml l|-8. CSH 2265 lb 2115.
CD 26 Results
.32
Time of death in l/h days after challengefg-8)
10th 11th I2th 13'th liith Survived
Section I.
CSH 2259 lb 2112
Al, Supernatant V - lj.-8
at once
Bl, Controls on
Section II.
CSH 2260 lb 2112
A2. Supernatant V -
at once
B2, Controls on l;"®
Sections I and II,
CSH 22S5 lb 2116
IX,1,1953 - 20 d. test
7!57 A,H.
Cl, Supernatant V - i^"®
in 20 d,
8:00 A,li,
Dl, Controls on U-®
8:03 A,M,
Cl, Supernatant 7 - U"®
in 20 d,
3:06 A,II,
D2, Controls on Ii~®
r * •
h 1 0/5
5 0/5
h 1 0/5
h 1 0/5
1 211 0/5
1 1  2 1 0/5
111 1 1/5 ^
1 1 2
i
V 5
* litter mates
33
CD 27« CSH 2263 lb 2115
CSH 226U lb 211s
VIII.26,1953
Conqjarison of supernatant HI and supernatant V — challenged at once. Super
natant III was prepared as usual, then divided in two parts - one part was
continued with removal of successive supernatants, the other part centrifuged
simultaneously, but each time sediment resuspended.
Groups
Sections 1 and II Al and A2, Supernatant III challenged (ii-8) at once.
B1 and B2, Supernatant V challenged (U-Q) at once.
C1 and 02. Controls on
Section I,
VIII.26,1953
8:20 - 10:10 A.M. Prepared 3U«U0 ml standard suspension lb in 2 lots of 7
spleens each - combined in tube 1.
10:10 - 10:25 Tube 1 - 5500 G/lO+5 rain.j supernatant I (21 ml) to tube 2.
10:29 - 10:Uli Tube 2 - 5500 G/lO+5 min.j supernatant II (19 ml) to tube 3.
10:50 - 11:05 Tube 3 - 5500 G/io+5 rain.; supernatant III 6.5 ml to tube ii,
9*0 ml to tube 5»
11:10 - 11:30 iubes and 5 - 8600 G/l5+5 min.; tube h sediment resuspended
- from tube 5 supernatant IV 8 ml to tube ?.'
11:35 - 11:55 Tubes and 6 - 86OO 0/15+5 min.; tube 1: sediment resuspended
- from tube 6 supernatant V to tube 7.
12:00 - 12:15 Tubes and 7 - 86OO G/15+5 min,; tube it sediment resuspended
- tube 7 supernatant VI removed and injected,
12:20 Inject supernatant IV (tube !i), Al - 1 ml per mouse.
12:15 Inject supernatant VI - "V" (tube 7), Bl - l ml per mouse.
Prepared dil. lt"8 during last run,
12?37 - 12:itO Challenged Al, Bl and C1 (controls) - ,2 ml ii"® -
CSH 2263 lb 2115,
3k
Section II,
105 - 2:it5 P.M. Prepared 31 ml standard suspension lb in 2 lots of 7 and 6
spleens - combined in tube 1.
2:50 - 3:05 lUbe 1 - 5500 G/lO+5 min.j supernatant I (20 ml) to tube 2,
3:10 - 3:25 Tube 2 - 5500 G/lO+5 min.j supernatant II (l8 ml) to tube 3.
3:30 - 3:U5 Tube 3 - 5500 G/lO+5 min.; supernatant III 6,5 ml to tube U»
9.0 ml to tube 5.
3:50 - U:10 Tubes 5 and 5 - 8600 G/15+5 min.; tube h sediment resuspended -
from tube 5 supernatant IV to tube 6,
1^:15 - ii:35 Tubes U and 6 - 8600 G/i5+5 min.; tube k sediment resuspended -
from tube 6 supernatant V to tube ?.
U:1|5 - 5:00 Tubes h and ? - 8600 G/l5+5 min.; tube it sedment resuspended
and injected, tube ? supernatant VI removed and injected
5*Oi4. Inject supernatant III (tube U), B2 - 1 nCL per mouse.
5:10 Inject supernatant VI = "V", A2 - 1 ml per mouse.
5:15 - 5:21 Challenge B2, A2 and 02 - .2 ml k'^ - CSH 226it lb 2115
dilution It-o prepared during centrifugation). Donor for this
challenging dilution (last spleen available) had died naturally a
little before last run, so removed spleen within a few minutes and
diluted to it~^ - held in ice until A2 and B2 treated before making
final dilutions.
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CD 27 Results
Section I.
CSH 2263 lb 2115 - U"®
VIII.26.1953
Al. Supernatant III
Bl, Supernatant "V"
Cl. Controls on U"® -
challenge at once
Section II.
CSH 22614 lb 2115
Donor died naturally before
spleen removed
ij-8 _ vial 1
5:1? H'l A2. Supernatant III
5^15 Ril 32. Supernatant "V"
5:21 HI C2. Controls on
challenge at once
Time of death in l/h days after
challenge (U'S)
9th 10th 11th
11 1
11 2
3
Survived
3A " Ih
* at 23 d. = "pad"
1/5 *
0/5
0/5
5/5
h/B
5/5
IX.7.1953
CSH 2267 lb 2117
Reinoculated after 12 days - A2, B2 and C2 on chance first challenge had
included no living cells. But death of one 32 mouse 2 days later (also 2cfcf
given same challenge dose in CD 25 - 20 d. testjproved IrO contained some
live cells on 8/26. '
10:03 am A2. Supernatant III
10:08 AM B2. Supernatant "V"
10:11 AM C2, Controls on
(CSH 226it)
10:11; AM 5 not previously
inoculated
9th 10th 11th 12th
1
13th Survived
3/5
3/U
0/5
/
0/5
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CD 28. CSH 2265 2116
CSH 2266 lb 2116
IX.1.1953
Supernatant III compared with supernatant V prepared from different lots of
standard suspension and centrifuged independently - challenged (l^-S) at once.
Groups
Sections I and II A1 and A2. 1.0 ml supernatant V (5 x 8600 G/lO+5)
Bl and B2. 1.0 ml supernatant III (3 x 5300 G/lO+5)
01 and C2. Controls on challenge (at once) li"®
Section I.
l^ilO - 5^10 A.ll. Prepared lh.75 ml standard suspension in two lots of 3 and
U spleens each. As removed, spleens placed in Ii ml iced saline
until minced - this saline used in suspending. Combined in tube 1.
SilO - 5:25 Tube 1 - 8600 G/lO+5 min.j supernatant I to tube 2.
3528 - 5!ii3 Tube 2 - 8600 G/lO+5 min.j supernatant II to tube 3.
3!U6 - 6:01 Tube 3 - 8600 G/lO+5 min.j supernatant III to tube it,
6:09 - 6:2ii Tube it - 8600 G/lO+3 min.j supernatant IV to tube 3-
6:26 - 6:iil Tube 3 - 8600 G/lO+3 min.j supernatant V (5"'' ml)
6:1+7 Inject supernatant V - 1.0 ml per mouse - into Al.
D^ing above centrifuging, prepared Ih ml standard suspension I5
(in tube 6) in two lots of 3 and I4. spleens each - spleens being
chilled immediately upon removal and all saline chilled and
suspension kept in ice bath.
6:1+3 - 6:58 Tube 6 - 3300 G/lO+5 min.j supernatant I to tube 7.
7!01 - 7j16 'Ibbe 7 - 3300 G/lO+3 min.j supernatant II to tube 8.
7:19 - 7:31+ Tube 8 - 3300 G/lO+5 min.j supernatant III to vial.
7:1+0 Inject Bl - 1.0 ml per mouse - supernatant III.
Dilution l+~8 prepared during last runs.
7:1+3 - 7:30 Challenge (i+-8) Al, 31, Cl. CSH 2265 lb 21l6.
37
Section II«
8s35 - 9:10 A.H, Prepared 15 ml standard suspension Iv in two lots of 3
spleens each - spleens into cold h ml saline immediately upon
removal,
9:lh - 9:29 Tube 1 - G60G G/iO+5 min.j supernatant I (10 ml) to tube 2,
9:31 - 9ih(> Tube 2 - 8600 G/lO+5 min,^ supernatant II (8 ml) to tube 3,
9:53 - 10:08 Tube 3 - 8600 G/lO+5 min.j supernatant III (7 ml) to tube ii,
10:11 - 10:26 Tube li - 8600 G/lO+5 min.; supernatant IV to tube B,
10:29 - 10:l4i4 Tube 5 - 8600 G/lO+5 min.j supernatant V - 5+ ml to vial.
10:50 Inject 1,0 ml supernatant V - A2.
During above centrifuging, prepared 15*5 ml standard suspension Iv
in two lots of 3 spleens each, kept cold from moment of removing
each spleen - to tube 6,
10:Ii8 - 11:03 Tube 6 - 5500 G/lO+5 min.j supernatant I (8 ml) to tube 7.
11:06 ■» 11:21 Tube 7 - 5500 G/lO+5 min.j supernatant II (7 ml) to tube 8,
11:25 - 11:1:0 Tube 8 - 5500 G/lO+5 min.j supernatant III - 5+ ml to vial.
11:1:5 Inject B2 - 1,0 ml supernatant III,
During above centrifuging prepared dilution l:-8.
11:51 - 11:59 Challenged A2, B2, C2 - .2 ml dilution 1:""^ - CSH 2266 I^j 2116,
CD 28 Results
Time of death in l/h days after challenge (U"®)
9th 10th nth 12th 13th lUth Survived
Section I.
CSH 2265 lb 2116
7:U5 ah
Al, 1.0 ml superna
tant V—chal
lenged in 1 hr.
2 1 1 1/5
7;U7 AH
Bl, 1,0 ml superna
tant III—chal
lenged in 7 min.
2 1 2/5
7:50 Alf
01. Controls on
challenge (U~®)
1 1 2 1 0/5
Section II.
CSH 2266 lb 2116
11:51 AM
A2.| 1 3 1/5
11:55 AM 1
B2. ';as above
1
1 1 2 1/5
11:55 AM /
02.'^
a
1 1 1 2 1/5
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CD 29. CSH 2267 lb 2117
CSH 2268 lb 2117
IX.7.1953
Continuing comparison of supernatant III (5000 G) and supernatant V (8600 G)
and adding supernatant III (11,000 G),
Groups
Sections I and II A1 and A2. 1.0 ml supernatant V (5 x 8600 G) challenged
in 2 hrs.
B1 and B2. 1.0 ml supernatant III (3 x 5500 G) challenged
in 1 hr.
C1 and 02. 1.0 ml supernatant III (3 x 11,000 G)
challenged in 8 min.
D1 and D2. Controls on challenge U"® given.
Section I.
5:20 - 6:10 Adl. Prepared 12.65 ml standard suspension I^ in 2 lots of 3
spleens each. Spleens immediately into iced saline upon removal -
combined in tube 1.
6:15 - 6t30 Tube 1 - 8600 G/lO+5 min.j supernatant I (9 ml) to tube 2.
6:35 - 6:50 Tube 2 - 8600 G/10+5 min,; supernatant II (8 ml) to tube 3*
6:55 - 7:10 Tube 3 - 8600 G/lO+5 min.j supernatant III (7 ml) to tube i;.
7:13 - 7:28 Tube h - 8600 G/lO+5 min.; supernatant IV (6.5 ml) to tube 5*
7:30 - 7:ii5 Tube 5 - 8600 G/lO+5 min.; supernatant V (5+ ml) - inject Al.
7:50 Inject Al - 1.0 ml supernatant V.
During above centrifuging prepared 12.80 ml standard suspension in
2 lots of 3 spleens each - (as above) - to tube 6.
7:50 - 8:05 lube 6 - 5500 G/lO+5 min.; supernatant I (10 ml) to tube 7#
8:10 - 8:25 Tube 7 - 5500 G/lO+5 rain.; supernatant II (7 ml) to tube 8,
8:28 - 8rli3 Tube 8 - 5500 G/IO+5 min«; supernatant III 5'^ ml - inject Bl.
8:50 Inject Bl - 1.0 ml supernatant III (5500 G)
During above centrifuging prepared 12,50 ml standard suspension lb
in 2 lots of 3 spleens each (as above) - combined in tube 9.
8:U6 - 9:01 Tube 9 - 11,000 G/lO+5 min.; supernatant I (7.5 ml) to tube 10.
9:05 - 9:20 Tube 10 - 11,000 G/IO+5 rain.; supernatant II (6,0 ml) to tube 11.
9:25 - 9:i:0 Tube 11- 11,000 G/lO+5 min.; supernatant III - inject Cl,
liO
9ih$ Inject C1 - 1.0 ml supernatant HI (11,000 G)
During above centrifuging prepared dilution and started
challenging•
9ihO - 9:57 Challenged - ,2 ml h"® - Al, Bl, Cl, D1 controls on ii-8.
CSH 2267 lb 2117.
Section II.
2:15 - 2;U5 P.M. Prepared ll)..75 ml standard suspension lb in 2 lots of 3
spleens each - kept chilled from moment of removing spleen (as
above) - combined in tube 1.
2:50 - 3:05 Tube 1 - 8600 G/IO+5 min.j supernatant I (10 ml) to tube 2.
3:06 - 3:23 Tube 2 - 8600 G/lO+5 min.; supernatant II (9 ml) to tube 3.
3:28 - 3:U3 Tube 3 - 8600 G/lO+5 min.j supernatant III (7 ml) to tube
3:1;7 - li:02 Tube Ij. - 8600 G/lO+5 min.; supernatant IV to tube 5.
k:OS - ii:20 Tube 5 - 8600 G/lO+5 min.; supernatant V inject A2 after tube
6 in centrifuge.
li:25 Inject A2 - 1.0 ml supernatant V,
During above centrifuging prepared 15.55 ml standard suspension lb
in 2 lots of 3 spleens each (as above) to tube 6.
ii;2i(. - h09 Tube 6 - 5500 G/lO+5 min.; supernatant I (10 ml) to tube 7.
l;:Ul - 1^:56 Tube 7 - 5500 G/lO+5 min.; supernatant II (7 ml) to tube 8,
5:00 - 5:l5 Tube 8 - 5500 G/lO+5 min.; supernatant III 5+ ml - inject B2.
5:20 Inject B2 - 1.0 ml supernatant III (5500 G).
During above centrifuging prepared 15.20 ml standard suspension lb
in 2 lots of 3 spleens each - (as above) - combined in tiibe 9.
5:l8 - 5:33 Tube 9 - 11,000 G/lO+5 rain.; supernatant I (10 ml) to tube 10.
5:37 - 5:52 Tube 10 - 11,000 G/lO+5 min.; supernatant II (7 ml) to tube 11.
5:55 - 6slO Tube 11 - 11,000 G/lO+5 min.; supernatant III 5+ ml - inject 02,
6:15 Inject C2 - 1.0 ml supernatant III (11,000 G). CSH 2268 lb 2117,
During above centrifuging prepared dilution J4-8,
6:10 - 6:25 Challenged ,2 ml U'^8 > A2 after 2 hrs,, B2 after 1 hr,, C2 after
7 min, D2 - controls on U~8,
CD 29 Results
bl
Time of death in l/k days
10th nth 12th 13th lUth Survived
Section I.
CSH 2267lb 2117
Al. 1,0 ml supernatant V
(8600 G) challenged
in 2 hrs.
Bl, 1,0 ml supernatant III
(5500 C) challenged
in 1 hr.
Cl, 1,0 ml supernatant III
(11,000 G) challenged
in 8 min.
Dl, Controls on challenge
Section n,
CSH 2268 lb 211?
A2. 1,0 ml supernatant V
(8600 G) challenged
in 2 hrs,
B2. 1,0 ml supernatant III
(5500 G) challenged in
1 hr,
C2, 1,0 ml supernatant III
(11,000 G) challenged
in 7 min,
D2, Controls on challenge
1 U/5
1  1 1 2/5
5/5 1
5/5 i
2 1 2/5
2 1
;
1 1/5
1 1
1
2 1/5
1
1
i
1
5/5 1
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Li initiating, directing and supervising the work under this contract,
Col. Joseph Victor, M.D. has been closely associated with every step. He made
frequent trips to Cold Spring Harbor for personal conferences, and by mail and
telephone, has been in continuous contact as the individual experiments have
been formulated and as the results have been recorded.
The underlying objective coordinating the diverse experiments has been to
determine whether similarities in the phenomena of resistance inducible
against certain bacteria and certain transplanted leukemias, indicate a coiranon
basic mechanism, so that further analysis in one case (leukemia) will illumiw
nate the other. Ihe general conclusion may be drawn that a common basic
mechanism is not indicated; that diverse courses of events may lead to sur
vival after a challenging dose (of different or the same pathogens) that is
lethal to the controls; hence, that survival under one set of conditions may
not a priori be equatable to survival under another set of conditions.
The concept is supported that the induction of resistance does not
establish a static state, but rather depends uncn the relative rates of the
hosts' reactions and of the proliferation of the challenging organisms. Any
influence modiiying the rate of either process may decide between death and
survival. Once an animal survives, the active resistance so acquired largely
determines the outcome of further challenging. The chief interest appears to
be in the initial steps that lead to survival after the first challenge. What
are the determining factors, in a given case, that are responsible for the
success of the hosts' reactions in out-running the growth of the lethal chal
lenging dose of the cells?
Within the case of line Ip leukemia, in hosts of the strain of origin,
more than one such factor appears to have been found. Previously it had been
learned that virtually 100^ survival could be ensured by treatrent with normal
tissue from an unrelated strain of mice, as well as by treatment with
thoroughly washed leukemic (line I^) cells after they had been subjected to
U60 for h minutes. Ihe work under this contract adds evidence of what appears
to be another factor influencing survival. This factor is found in the super
natant from saline suspensions of cells from line leukemic spleens.
Although the progress of the work has been seriously handicapped by the
failure to concentrate this factor enough to yield a high proportion of sur
vivors, it seems highly probable that this factor is not a direct product of
the leukemic cells, but was elaborated 1:^ the donor of the spleen in reacting
to the invading leukemic cells with which it bad been inoculated.
Since the challenging dose may be inoculated immediately after the super
natant or the two may even be mixed and injected together with as much protec
tion as at 2, 6, or 20 days, it appears that the factor responsible for the
survivals is independent of the leukemic cells, in spite of the fact that the
production of supernatants absolutely cell-free has been found to be difficult
and uncertain. If a few cells remained in the supernatant these would merely
add to the lethality of the challenging dose when the two are combined. The
experimental procedure in this case has merely reduced the number of leukemic
cells to a minimal lethal dose without diluting the protective factor in the
original "standard" cell suspension.
The resistance found when the challenging dose was delayed for 20 days
raises a question as to the possible action of cells that might remain in the
supernatant. According to previous experiments with heated line It
cells, a few living leukemic cells were necessary to obtain full resistance
persisting for 20 days after injection of the heated cells. In the last
quarter of this contract year, an attempt has been made to determine whether
living cells were also responsible for the resistance found 20 days after
treatment with a supernatant. But the year has terminated before an answer
to this question could be obtained.
The detailed protocols have been recorded in the four quarterly progress
reports. Without conimenting upon experiments concerned with testing techniques
that were not adopted, the results contribute to the following questions;
Will dog blood, frozen or fresh, induce resistance to a challenging dose
of line lb leukemia given in 1, 2 or 3 days? (CD 3 and 1|) The data indicate
emphatically that this is not the case.
Will repeated treatments with line lb leukemic cells after being heated
U60/1U min, produce more persistent resistance than a single treatment?
(CD 6 and 8) When challenged at lli days, somewhat more of the mice receiving
three treatments survived than of those receiving one treatment.
Can resistance be induced by supernatants from line lb cell suspensions?
The majority of the 29 experiments deal with this question. The early ones
were based on the idea that a substance responsible for resistance was in some
way produced by, or was a part of, the leukemic cells, and might be separated
from the cells by appropriate means. Thus, before testing supernatants for
protective properties, the cell suspensions were rotated in an ice bath and at
37*^; they were heated (i;6°/ll!. mini) and repeatedly centrifuged and resuspended
in fresh saline to see if a protective substance was removed or was contin
uously produced; the cells were disrupted hy distilled water and by the
shearing action of forceable "squirting"; the cell suspensions were incubated
at 37°, Supposing that the protective material might be unstable, the time of
preparation of the cell suspension was cut down by dividing each experiment
into two independent sections: the material was kept cold by ice baths and
finally by carrying out aH operations, short of injecting the mice, in a
20-room, But under no condition was enough resistance obtained to protect
more than $0% of the iTiice, and in most cases only between 10% and 30%, No
evidence was found to support the assumption that the material in the superna
tant responsible for this resistance originated in or was produced by the
leukendc cells. None of the various treatnents of the leukeraic cell suspen
sions increased the resistance induced the supernatants from entirely un
treated cell suspensions.
Since the resistance induced by dog blood against certain bacteria and
heated leukemic cells was at its height in 2 daysj the challenge in mapy ex
periments was given in 2 days. But varying this time from 0 to 25 days gave
virtually the same degree of resistance at all times tested.
Table 1
Variation in Time of Challenge (dilution U"®) after Treatment
with Supernatant III
Experiments are included in which the cell suspensions were rotated as well as
centrifugedj but all cases with erratic controls are omitted. Survivors/
nuraber in group.
Day of challenge
0  1 2 6 20 22 25
19/60 h/10 17/50 10/20 VlO 1/5 3/10
This result stands in striking contrast to the results for heated cells,
which showed a rapid strengthening of resistance for two days followed by a
rapid weakening after 3 days. This evidence of different mechanisms in the
resistance from supernatants and from heated cells is supported by the fact
that after three successive washings, the heated cells were as effective in
inducing resistance as at first, while the supernatants from resuspended cells,
whether heated or not, were ineffective.
